Related Experiment Video
Updated: Aug 9, 2026
19:57
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Summary
New medicines offer cost-effective solutions, but premature market entry of expensive drugs without sufficient clinical evidence is a concern. National decisions on expensive treatments require robust efficacy and pharmacoeconomic data.
Area of Science:
- Pharmacoeconomics
- Health Technology Assessment
- Drug Development
Background:
- Underutilization of cost-effective medicines is a concern.
- Premature market introduction of expensive drugs lacking adequate clinical studies is problematic.
- New drugs for serious conditions offer hope but require thorough evaluation.
Purpose of the Study:
- To highlight concerns regarding the premature introduction of expensive drugs.
- To emphasize the need for post-marketing studies for certain treatments.
- To advocate for evidence-based decision-making for expensive therapies.
Main Methods:
- Review of current practices in drug approval and market entry.
- Analysis of the role of clinical efficacy studies and pharmacoeconomic assessments.
- Discussion of national versus local decision-making for expensive treatments.
Main Results:
- Inadequate clinical studies precede market entry for some drugs.
- Post-marketing studies are sometimes required for patient access.
- Decisions on expensive treatments are often influenced by budget pressures.
Conclusions:
- Decisions on expensive treatments must be based on adequate clinical efficacy and independent pharmacoeconomic assessment.
- National-level decision-making is crucial for equitable access and resource allocation.
- Balancing budgets should not override the need for rigorous drug evaluation.
Related Concept Videos
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:20Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).